NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
NRx Pharmaceuticals (Nasdaq: NRXP) reported third-quarter results and began commercial sales following October 2026 FDA approval of preservative-free ketamine. Net patient service revenue rose to $1.2 million from $0.2 million a year earlier. Net loss narrowed to $2.2 million, or $0.05 per share, from $5.9 million, or $0.27 per share, while operating loss widened to $8.1 million from $4.0 million.
Selling began the week of November 9; the first order is received and shipments are scheduled by January 2027. Quarter-end cash was $19.8 million, with no convertible debt. NRx aims to submit a rolling NRX-100 drug application by year-end 2026, supported by a Yale collaboration. NRx Defense Systems received an $11.25 million DARPA contract for a Phase 3 trial. NRx also introduced subcutaneous ketamine candidate NRX-200, with initial human testing targeted for September 2027.
NRx Pharmaceuticals (Nasdaq: NRXP) will release its third-quarter 2026 financial results before the market opens on November 17, 2026.
The company will also provide a corporate update and host a conference call at 8:00 a.m. ET that day. The results will be available on its investor relations website, with a live webcast accessible through the website’s events page.
NRx Pharmaceuticals (Nasdaq: NRXP) has begun selling its FDA-approved, U.S.-manufactured preservative-free ketamine through a newly operational national sales force. The 17-person team has relationships with purchasers responsible for approximately 80% of current U.S. ketamine sales. NRx targets initial supply agreements and preorders for late 2026, with shipments scheduled to begin in January 2027.
The company expects gross and net sales margins above 50% from manufacturing and sales efficiencies. Its blow-fill-seal process forms, fills and seals a vial in one manufacturing step. NRx has contracted with German equipment suppliers to double its South Carolina manufacturing footprint, potentially adding other U.S.-made sterile injectable products. Ketamine has been listed in shortage since 2018.
NRx Pharmaceuticals (Nasdaq: NRXP) received FDA approval of its generic drug application for preservative-free ketamine ahead of the agency’s goal date.
The approval preceded the November 10 target. The formulation contains no benzethonium chloride, a preservative used in existing ketamine injections. Manufactured commercial supply is on hand; NRx said it can now label the product and supply American hospitals and clinics.
The product is manufactured in the United States with Nephron Pharmaceuticals in West Columbia, South Carolina. NRx aims to address the shortage of traditional glass-bottled ketamine through high-volume “blow-fill-seal” manufacturing technology. The company said ketamine injection has been in short supply since 2018 and currently appears on the FDA drug shortage list.
NRx Pharmaceuticals (Nasdaq: NRXP) will host a conference call on October 30, 2026, to discuss a regulatory milestone for preservative-free ketamine.
The call is scheduled for 8:30 a.m. ET and will also cover next steps on the commercial launch. The company plans to issue a press release with details before the market opens that morning. A live webcast will be available on its investor relations website, with telephone access also available.
NRx Pharmaceuticals (Nasdaq: NRXP) completed manufacturing process validation for preservative-free ketamine, producing three commercial lots ahead of its regulatory review goal date.
The lots were produced under commercial conditions in compliance with FDA Good Manufacturing Practices. Process validation is the final manufacturing step required to demonstrate that compliance. Two-year, real-time room-temperature stability testing showed no deterioration in purity, potency, or sterility without preservatives. NRx believes these data support a labeled shelf life of three years or longer.
Commercially releasable supply is on hand, but release remains subject to FDA approval of the Abbreviated New Drug Application (ANDA). The regulatory review goal date is November 10, 2026. NRx said it is positioned to supply the drug-shortage product immediately upon approval, with Nephron Pharmaceuticals as its manufacturing partner.
NRx Pharmaceuticals (NRXP) received an FDA labeling review letter requesting minor changes to its preservative-free ketamine product’s submitted label.
All requested changes were classified as “MINOR.” The FDA requested sample labeling using the proposed proprietary product name, which remains under review, ahead of the November 10, 2026 goal date for the abbreviated new drug application. This application is the generic-drug approval pathway.
NRx is completing final manufacturing process validation runs, which verify the manufacturing process, to comply with product launch requirements. Separately, NRx has initiated a new drug application filing for NRX-100, its preservative-free intravenous ketamine, for suicidal ideation in patients with depression, including bipolar depression.
NRx Pharmaceuticals (NRXP) subsidiary NRx Defense Systems received an initial DARPA prime contract of $11,177,757.27 to evaluate a depression treatment. The FDA-approved SPARC-TMS trial will begin enrolling patients to test whether a single day of transcranial magnetic stimulation (TMS), combined with investigational drug NRX-101, can effectively treat major depressive disorder.
The trial will run at Harvard Medical School’s McLean Hospital, Arizona State University and HOPE Therapeutics, with plans to expand to military hospitals. Its foundation includes a completed DARPA-funded randomized trial and published real-world findings of 91% treatment response and 69% remission three months after traditional TMS plus D-cycloserine. NRx says SPARC-TMS could serve as an FDA registration study for NRX-101 with TMS in treatment-resistant depression if those results are replicated.
NRx Pharmaceuticals (NRXP) reports that the FDA has reclassified an amendment to its Abbreviated New Drug Application for preservative-free ketamine from a Major Amendment to a Minor Amendment, and has revised the Generic Drugs User Fee Act (GDUFA) goal date to November 10, 2026.
The FDA communication, from the Director of Regulatory Operations of the Office of Generic Drugs, states that the reclassified amendment will not require a substantial expenditure of FDA resources. The company characterizes this product as a strategic drug intended to address a drug shortage. NRx is developing NRX-100 (preservative-free intravenous ketamine) for suicidal ideation in depression, including bipolar depression, and NRX-101 (oral D-cycloserine/lurasidone) for suicidal bipolar depression, both of which have received expedited FDA designations.
GeNeuro, Inc., an NRx company (NRXP) received a European patent (EP 3 570 878 B1) for GNK-301, a monoclonal antibody drug candidate targeting Amyotrophic Lateral Sclerosis (ALS).
The patent, co-owned with the US Dept. of Health and Human Services, covers an anti‑HERV K Envelope antibody that has blocked K Env–induced neurotoxicity in laboratory animals and human motor neuron cells. It complements two previously granted US patents (10,723,787 and 10,981,977) and expands a portfolio of more than 25 issued and pending HERV-related patents. GeNeuro has initiated cGMP manufacture of GNK-301 and plans human Phase 1 trials in ALS in the US and Europe. A related antibody, Temelimab, has already been tested in five trials in more than 400 participants, showing statistically significant reductions in neurodegeneration on MRI and no Serious Adverse Events.